Abstract:Abstract Background lncRNA-CDKN2B antisense RNA 1 (ANRIL) and SRY-box transcription factor 9 (SOX9) has abnormal expression in many tumors including glioma, but the underlying molecular mechanism is unclear. This study set out to investigate the serum lncRNA-ANRIL and SOX9 levels in glioma patients and their effects on prognosis. Methods We enrolled 142 glioma patients admitted to our hospital from May 2014 to May 2016 into the research group (RG) and 120 healthy subjects receiving concurrent physical examinations into the control group (CG). Fasting peripheral blood (4 mL each) wa s sampled from subjects from the two groups. Using the quantitative real-time polymerase chain reaction (qRT-PCR), lncRNA-ANRIL and SOX9 were measured to explore their values in the early diagnosis of glioma. Patients from RG were followed up for 3 years to analyze the influence of lncRNA-ANRIL and SOX9 on patient prognosis. We purchased glioma cell lines U251 and U87 and grouped them according to the transfection of different plasmids. We conducted CCK8 assay to test cell proliferation, Transwell assay to test cell invasion, the flow cytometry to test cell apoptosis, and Western Blot assay to measure bcl-2 and bax protein levels. Results ANRIL and SOX9 were evidently higher in RG than in CG ( P <0.01). The receiver operating characteristic (ROC) curve revealed that the diagnostic sensitivity of ANRIL combined with SOX9 for glioma was 81.62%, and the specificity was 90.83% ( P <0.01). ANRIL and SOX9 were closely related to tumor grade, tumor diameter, distant metastasis, and family history of glioma ( P <0.01). In total, 135 patients were successfully followed up (95.07%). Patients with high levels of ANRIL and SOX9 had a markedly poorer prognosis than those with low levels ( P <0.05). ANRIL and SOX9 were markedly higher in glioma cell lines (U251 and U87) than in normal brain cells ( P <0.01). The proliferation and invasion of U251 cells were notably reduced after the transfection of ANRIL and SOX9 inhibitory sequences ( P <0.01), but the apoptosis was notably increased ( P <0.01). Bcl-2 expression was markedly increased in lncRNA-ANRIL-inhibitor and SOX9-inhibitor ( P <0.01), while bax expression was markedly reduced in lncRNA-ANRIL-inhibitor and SOX9-inhibitor ( P <0.01). Conclusion lncRNA-ANRIL and SOX9 levels were higher in glioma patients than in healthy people. High-lncRNA-ANRIL and SOX9 levels were strongly associated with unfavorable prognosis of patients. The testing of biological behaviors revealed that lncRNA-ANRIL and SOX9 worked as tumor-promoting genes in glioma.

Analysis of Long Noncoding RNA ZNF667-AS1 as a Potential Biomarker for Diagnosis and Prognosis of Glioma Patients

DNAJC10 Correlates with Tumor Immune Characteristics and Predicts the Prognosis of Glioma Patients

A Long Noncoding Rna Zeb1-As1 Promotes Tumorigenesis and Predicts Poor Prognosis in Glioma

Independent Prognostic Factor of Low-Expressed LncRNA ZNF667-AS1 for Cervical Cancer and Inhibitory Function on the Proliferation of Cervical Cancer.

ZNF503-AS2 is a Promising Therapeutic Target and is Associated with the Immune Microenvironment in Glioma

Upregulation of long noncoding RNA zinc finger antisense 1 enhances epithelial–mesenchymal transition in vitro and predicts poor prognosis in glioma

Upregulation of the Long Non-Coding RNA SNHG1 Predicts Poor Prognosis, Promotes Cell Proliferation and Invasion, and Reduces Apoptosis in Glioma.

Prognostic value of long non-coding RNA ZEB1-AS1 in Chinese cancer patients: A Meta-analysis.

Serum lncRNA-ANRIL and SOX9 expression levels in glioma patients and their relationship with poor prognosis

Up-Regulation of Long Non-Coding RNA AB073614 Predicts a Poor Prognosis in Patients with Glioma

LINC00174 is a Favorable Prognostic Biomarker in Glioblastoma Via Promoting Proliferative Phenotype.

LncRNA FOXD1-AS1 acts as a potential oncogenic biomarker in glioma.

In Silico Analysis Identifies Upregulated Lncrna DLGAP1-AS1 Which is Correlated to Poor Prognosis and Promotes Cell Proliferation in Glioblastoma

Long Non-Coding RNA LINC01503 Predicts Worse Prognosis in Glioma and Promotes Tumorigenesis and Progression Through Activation of Wnt/β-catenin Signaling.

Prognostic and clinicopathological significance of long non-coding RNA in glioma

Exploring the multifaceted role of key lncRNA in glioma: From genetic expression to clinical implications and immunotherapy potential

Up‑regulation of Lncrna PXN-AS1-L is Associated with Unfavorable Prognosis in Patients Suffering from Glioma.

Long non-coding RNAs as epigenetic mediator and predictor of glioma progression, invasiveness, and prognosis

Diagnostic and Prognostic Potentials of Long Noncoding RNA ELF3-AS1 in Glioma Patients

Novel LncRNA OXCT1-AS1 indicates poor prognosis and contributes to tumorigenesis by regulating miR-195/CDC25A axis in glioblastoma

Increased Expression of Lncrna ZEB1-AS1 in Non-Small Cell Lung Cancer is Associated with Poor Prognosis